Search results for " TOXICOLOGY AND PHARMACEUTICS"

showing 10 items of 461 documents

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

0301 basic medicinemedicine.medical_specialtyMolecular PharmacologyNeuropharmacology & PsychopharmacologyTraumatic brain injurySolid baseBrain damageNeuroprotectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTraumatic brain injury0302 clinical medicinePrimary preventionmedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineErythropoietin; Neuroprotection; Traumatic brain injuryErythropoietinCause of deathGeneral Immunology and Microbiologybusiness.industryArticlesGeneral MedicineOpinion Articlemedicine.diseaseNeuroprotectionClinical trial030104 developmental biologyErythropoietinmedicine.symptombusinessNeuroscience030217 neurology & neurosurgerymedicine.drugF1000Research
researchProduct

Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy

2016

Paola Di Carlo,1 Giuliana Guadagnino,1 Palmira Immordino,1 Giovanni Mazzola,2 Pietro Colletti,2 Ilenia Alongi,1 Lucia Adamoli,1 Francesco Vitale,1 Alessandra Casuccio1 1Department of Sciences for Health Promotion and Mother-Child Care “G D’Alessandro”, University of Palermo, 2Department of Medicinal Clinics and Emerging Diseases, “Paolo Giaccone” Polyclinic University Hospital, Palermo, Italy Aim: The authors examined a cohort of HIV-positive outpatients at the AIDS Center of Palermo University in Italy in order to identify factors related to the frequency of their visits to the outpatient facility for health care services.Methods: Two hundr…

0301 basic medicinemedicine.medical_specialtyMultivariate analysisSettore MED/17 - Malattie Infettivehard-to-reach groups030106 microbiologyHuman immunodeficiency virus (HIV)Medicine (miscellaneous)HIV Outpatient Servicemedicine.disease_causeSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineOutpatient facilityAmbulatory careAcquired immunodeficiency syndrome (AIDS)CD4+ T-cell countHealth careMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)Access to care; CD4+ T-cell count; Hard-to-reach groups; HIV infection; HIV outpatient service; Resource use; Social Sciences (miscellaneous); Medicine (miscellaneous); Health Policy; Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchaccess to carelcsh:R5-920business.industryHealth PolicyUnivariatemedicine.diseaseHIV infectionresource usePatient Preference and AdherenceEmergency medicineCohortbusinesslcsh:Medicine (General)Hard-to-reach groupSocial Sciences (miscellaneous)
researchProduct

Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

2017

Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, “self-antigens”, that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer…

0301 basic medicinemedicine.medical_treatmentchemical and pharmacologic phenomenaBiochemistryCancer Vaccines03 medical and health sciencesMice0302 clinical medicineImmune systemCancer immunotherapyAdjuvants ImmunologicDrug DiscoverymedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsMUC1PharmacologyVaccines SyntheticbiologyChemistryImmunogenicityOrganic ChemistryMucin-1GlycopeptidesDendritic CellsVirologyGlycopeptideToll-Like Receptor 3030104 developmental biologyPoly I-C030220 oncology & carcinogenesisTLR3biology.proteinMolecular MedicineAntibodyAdjuvantChemMedChem
researchProduct

MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma

2016

Hypoxia is a common feature in solid tumours. In glioma, it is considered the major driving force for tumour angiogenesis and correlates with enhanced resistance to conventional therapies, increased invasiveness and a poor prognosis for patients. Here we describe, for the first time, that miR675-5p, embedded in hypoxia-induced long non-coding RNA H19, plays a mandatory role in establishing a hypoxic response and in promoting hypoxia-mediated angiogenesis. We demonstrated, in vitro and in vivo, that miR675-5p over expression in normoxia is sufficient to induce a hypoxic moreover, miR675-5p depletion in low oxygen conditions, drastically abolishes hypoxic responses including angiogenesis. In …

0301 basic medicinemiRNA675AngiogenesisMedicine (miscellaneous)RNA-binding proteinAngiogenesis; Glioma; HuR; Hypoxia; miRNA675; Optical imaging; VHL; Medicine (miscellaneous); Pharmacology Toxicology and Pharmaceutics (miscellaneous)BiologyToxicology and Pharmaceutics (miscellaneous)Cell LineELAV-Like Protein 1Miceoptical imaging03 medical and health sciencesSettore BIO/13 - Biologia ApplicataStress PhysiologicalIn vivoVHLGliomamicroRNAmedicineAnimalsHumansPharmacology Toxicology and Pharmaceutics (miscellaneous)PharmacologyAngiogenesis; HuR; VHL.; glioma; hypoxia; miRNA675; optical imagingMessenger RNANeovascularization PathologichypoxiaVHL.RNAGliomaHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitmedicine.disease3. Good healthAngiogenesiMicroRNAs030104 developmental biologyImmunologyCancer researchHeterograftsHuRAngiogenesismedicine.symptomResearch PaperTheranostics
researchProduct

Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher d…

2018

Anca Zimmermann,1 Radu A Popp,2 Heidi Rossmann,3 Simona Bucerzan,4 Ioana Nascu,4 Daniel Leucuta,5 Matthias M Weber,1 Paula Grigorescu-Sido41Department of Endocrinology and Metabolic Diseases, 1st Clinic and Polyclinic of Internal Medicine, University of Mainz, Mainz, Germany; 2Department of Medical Genetics, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 3Institute for Clinical Chemistry and Laboratory Medicine, University of Mainz, Mainz, Germany; 4Center of Genetic Diseases, 1st Pediatric Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 5Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy, Cluj-Napoca, RomaniaPurpose: Oste…

0301 basic medicinemusculoskeletal diseasesmedicine.medical_specialtyTherapeutics and Clinical Risk ManagementOsteoporosisGaucher diseasegene variantsCalcitriol receptorBone remodeling03 medical and health sciencesOsteoprotegerinInternal medicineGenotypecalcitonin receptormedicinevitamin D receptorPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCalcitonin receptorOriginal ResearchChemical Health and Safetybiologybusiness.industryGeneral Medicinemedicine.diseaseosteoporosis030104 developmental biologyEndocrinologyosteoprotegerinOsteocalcinbiology.proteinbusinessSafety ResearchEstrogen receptor alphaTherapeutics and Clinical Risk Management
researchProduct

New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation.

2018

New thiazole nortopsentin analogues were conveniently synthesized and evaluated for their activity as inhibitors of biofilm formation of relevant Gram-positive and Gram-negative pathogens. All compounds were able to interfere with the first step of biofilm formation in a dose-dependent manner, showing a selectivity against the staphylococcal strains. The most active derivatives elicited IC50 values against Staphylococcus aureus ATCC 25923, ranging from 0.40&ndash

0301 basic medicinethiazole derivativeAquatic OrganismsIndolesDrug ResistancePharmaceutical ScienceBacterial growthAntibiofilm agentmedicine.disease_cause01 natural scienceschemistry.chemical_compoundDrug Discoveryanti-virulence agents; antibiofilm agents; marine alkaloids; nortopsentin analogues; thiazole derivatives; Anti-Bacterial Agents; Aquatic Organisms; Biofilms; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Staphylococcal Infections; Staphylococcus aureus; Thiazoles; Drug Resistance; Bacterial; Anti-virulence agents; Antibiofilm agents; Marine alkaloids; Nortopsentin analogues; Thiazole derivativesPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Aquatic OrganismBiofilmBacterialImidazolesantibiofilm agentsStaphylococcal InfectionsAnti-Bacterial Agentsnortopsentin analoguesBiochemistryStaphylococcus aureusStaphylococcus aureumarine alkaloidsthiazole derivativesSelectivityHumanStaphylococcus aureusAnti-virulence agentNortopsentin analogueArticle03 medical and health sciencesInhibitory Concentration 50Anti-Bacterial AgentDrug Resistance BacterialIc50 valuesmedicineHumansThiazoleImidazoleStaphylococcal Infection010405 organic chemistryBiofilmSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesmarine alkaloidThiazoles030104 developmental biologychemistrylcsh:Biology (General)anti-virulence agentsIndoleBiofilmsThiazoleMarine drugs
researchProduct

Analysis of the Transcriptome of the Red Seaweed Grateloupia imbricata with Emphasis on Reproductive Potential

2018

Grateloupia imbricata is an intertidal marine seaweed and candidate model organism for both industry and academic research, owing to its ability to produce raw materials such as carrageenan. Here we report on the transcriptome of G. imbricata with the aim of providing new insights into the metabolic pathways and other functional pathways related to the reproduction of Grateloupia species. Next-generation sequencing was carried out with subsequent de novo assembly and annotation using state-of-the-art bioinformatic protocols. The results show the presence of transcripts required for the uptake of glycerol, which is a specific carbon source for in vitro culture of G. imbricata and nucleotide …

0301 basic medicineved/biology.organism_classification_rank.speciescarbon sourcesPharmaceutical ScienceRed algaetranscriptome shotgun assemblyreproductionTranscriptome03 medical and health scienceschemistry.chemical_compoundBiosynthesisgrowth regulatorsDrug DiscoveryModel organismlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)red algaeMethyl jasmonatebiologyved/biologybiology.organism_classificationSporeMetabolic pathway030104 developmental biologylcsh:Biology (General)chemistryBiochemistryPolyamineMarine Drugs
researchProduct

A putative antiviral role of plant cytidine deaminases

2014

[Background]: A mechanism of innate antiviral immunity operating against viruses infecting mammalian cells has been described during the last decade. Host cytidine deaminases (e.g., APOBEC3 proteins) edit viral genomes, giving rise to hypermutated nonfunctional viruses; consequently, viral fitness is reduced through lethal mutagenesis. By contrast, sub-lethal hypermutagenesis may contribute to virus evolvability by increasing population diversity. To prevent genome editing, some viruses have evolved proteins that mediate APOBEC3 degradation. The model plant Arabidopsis thaliana genome encodes nine cytidine deaminases ( AtCDAs), raising the question of whether deamination is an antiviral mec…

0301 basic medicinevirusesPopulation030106 microbiologyDeaminationAntiviral innate immunityGenomeGeneral Biochemistry Genetics and Molecular BiologyVirusError catastrophePararetrovirusGene product03 medical and health scienceschemistry.chemical_compoundPlant-virus interactionGenome editingPlant-Environment InteractionsVirologyHypermutagenesisArabidopsis thalianaGeneral Pharmacology Toxicology and PharmaceuticseducationGeneGeneticseducation.field_of_studyCauliflower mosaic virusGeneral Immunology and MicrobiologybiologyHost (biology)fungifood and beveragesCytidineGeneral MedicineArticlesbiology.organism_classificationVirologyVirus evolution030104 developmental biologychemistryMutational spectrumPlant Genetics & Gene ExpressionViral evolutionCauliflower mosaic virusResearch Article
researchProduct

2021

The coronavirus pandemic has affected more than 150 million people, while over 3.25 million people have died from the coronavirus disease 2019 (COVID-19). As there are no established therapies for COVID-19 treatment, drugs that inhibit viral replication are a promising target; specifically, the main protease (Mpro) that process CoV-encoded polyproteins serves as an Achilles heel for assembly of replication-transcription machinery as well as down-stream viral replication. In the search for potential antiviral drugs that target Mpro, a series of cembranoid diterpenes from the biologically active soft-coral genus Sarcophyton have been examined as SARS-CoV-2 Mpro inhibitors. Over 360 metabolite…

0303 health sciencesProteasebiologySarcophytonChemistrymedicine.medical_treatmentIn silicoPharmaceutical Sciencemedicine.disease_causebiology.organism_classification01 natural sciences0104 chemical sciences010404 medicinal & biomolecular chemistry03 medical and health sciencesBiochemistryViral replicationDrug DiscoverymedicineHIV Protease InhibitorStructure–activity relationshipPharmacology Toxicology and Pharmaceutics (miscellaneous)Darunavir030304 developmental biologymedicine.drugCoronavirusMarine Drugs
researchProduct

Innovative Green Technologies of Intensification for Valorization of Seafood and Their By-Products

2019

The activities linked to the fishing sector generate substantial quantities of by-products, which are often discarded or used as low-value ingredients in animal feed. However, these marine by-products are a prominent potential good source of bioactive compounds, with important functional properties that can be isolated or up-concentrated, giving them an added value in higher end markets, as for instance nutraceuticals and cosmetics. This valorization of fish by-products has been boosted by the increasing awareness of consumers regarding the relationship between diet and health, demanding new fish products with enhanced nutritional and functional properties. To obtain fish by-product-derived…

030309 nutrition & dieteticsEmerging technologiesmedia_common.quotation_subjectPharmaceutical ScienceCosmeticsReviewCosmetics03 medical and health sciencesIngredient0404 agricultural biotechnologyNutraceuticalinnovative green technologieshigh-added value compoundsDrug DiscoveryFish ProductsAdded valueAnimalsHumansQuality (business)Ultrasonics14. Life underwaterPharmacology Toxicology and Pharmaceutics (miscellaneous)functional foodsmedia_common0303 health sciencesBiological Productsseafood by-productsSupercritical fluid extractionChromatography Supercritical FluidGreen Chemistry Technology04 agricultural and veterinary sciencesFish products040401 food scienceSeafoodDietary SupplementsBiochemical engineeringBusiness
researchProduct